Indocyanine Blue as a New Option for Better NIR Imaging
Author Information
Author(s): Yamashita Atsushi, Jang Paul, Bao Kai, Kashiwagi Satoshi, Frangioni John V., Choi Hak Soo, Morozova-Roche Ludmilla A.
Primary Institution: Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School
Hypothesis
Can indocyanine blue (ICB) serve as a functional alternative to indocyanine green (ICG) for enhanced 700 nm near-infrared imaging?
Conclusion
Indocyanine blue (ICB) shows rapid clearance and lower background signals compared to indocyanine green (ICG), making it a promising candidate for clinical imaging applications.
Supporting Evidence
- ICB demonstrated peak absorption and emission approximately 100 nm shorter than ICG.
- ICB exhibited favorable solubility and optical properties in aqueous environments.
- ICB shows rapid systemic clearance, likely due to its lower molecular weight.
- Dual-channel imaging of tumors and lymph nodes was achieved using ICB.
Takeaway
This study found that a new dye called indocyanine blue can help doctors see better during surgeries by showing images more clearly and quickly than the older dye.
Methodology
The study involved in vitro and in vivo evaluations of ICB's optical properties, pharmacokinetics, and biodistribution in CD-1 mice.
Potential Biases
The authors have potential conflicts of interest due to affiliations with Curadel Pharma.
Limitations
Further studies are needed to evaluate the safety profile of ICB before its clinical application.
Participant Demographics
CD-1 mice were used for in vivo experiments.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website